Roots Analysis has announced the addition of “Squamous Non-small Cell Lung Cancer Market, 2021-2031” report to its list of offerings.
Success of approved squamous non-small cell lung cancer therapies, such as Keytruda®, Opdivo® and Portrazza®, has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of these therapies to effectively treat NSCLC, an aggressive form of lung carcinoma, justifies its potential as a promising disease management recourse. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
To order this 122+ page report, which features 81+ figures, please visit https://www.rootsanalysis.com/....reports/squamous-non
Key Market Insights
More than 85 product candidates are being investigated to treat metastatic or advanced squamous NSCLC patients
More than 78% of the therapies are being evaluated in early stages, either as monotherapies or in combination with other products. Further, majority of these therapies (45%) are designed for administration via the intravenous route. It is worth highlighting that, till date, five biologics and one small molecule have been approved for the treatment of squamous NSCLC.
Several big pharma players have an advanced pipeline of drugs targeting squamous NSCLC
Over 34 companies engaged in this domain represent large / very large businesses. Although biologics emerged as the most prominent type of molecule in the overall pipeline, big pharma players were observed to prefer developing small molecules against lung carcinomas. Interestingly, 53% of such firms are based in North America.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/squamous-non
Key Questions Answered
What are the prevalent R&D trends related to squamous non-small cell lung cancer?
What are the key challenges faced by stakeholders engaged in this domain?
What are the principal therapies being developed by the industry players?
Who are the leading industry and non-industry players in this market?
What are the contributions of big pharma players in this field?
What are the key geographies where research on squamous non-small cell lung cancer is being conducted?
Who are the key investors in this domain?
Who are the key opinion leaders / experts in this field?
What kind of partnership models are commonly adopted by industry stakeholders?
What are the factors that are likely to influence the evolution of this upcoming market?
For additional details, please visit
https://www.rootsanalysis.com/....reports/squamous-non or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. RAS Targeting Therapies Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
